Waks, Adrienne G.
Martínez-Sáez, Olga
Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Braso-Maristany, Fara
Pascual, Tomás http://orcid.org/0000-0001-8431-3183
Cortés, Javier http://orcid.org/0000-0001-7623-1583
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Article History
Accepted: 15 August 2024
First Online: 13 September 2024
Competing interests
: A.G.W. has acted as a speaker for AstraZeneca and as a consultant/adviser to AMBRX and AstraZeneca and has received institutional research funding from Genentech, Gilead, Macrogenics and Merck. P.T. has acted as an adviser and/or consultant to AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Lilly, Menarini/Steamline, Novartis and Roche, and has received institutional research funding from AstraZeneca. F.B.-M. reports patents filed as a co-inventor (PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369), and part-time employment by Reveal Genomics. T.P. has acted as a speaker for AstraZeneca, Pfizer and Novartis, and has acted as a consultant to Novartis. J.C. has acted as a consultant and/or adviser to Abbvie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Ellipses, Expres2ion Biotechnologies, Gemoab, Gilead, Hibercell, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme, Menarini, Reveal Genomics, Roche, Seattle Genetics, Scorpion Therapeutics and Zymeworks; has received honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Stemline Therapeutics; has received institutional research funding from Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer, Eisai, Guardant Health, Hoffmann-La Roche, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Queen Mary University of London and Roche Iqvia; owns stock in MAJ3 Capital (and a relative owns stock in Leuko); has received travel support from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Stemline Therapeutics; and is listed as a co-inventor on patents WO 2014/199294A and US 2019/ 0338368 A1. S.M.T. has acted as a consultant and/or adviser to Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Bayer, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, CytomX Therapeutics, Daiichi Sankyo, eFFECTOR, Eisai, Eli Lilly, Genentech/Roche, Gilead, Hengrui USA, Incyte Corp, Jazz Pharmaceuticals, Johnson & Johnson, Menarini/Stemline, Merck, Natera, Novartis, Pfizer (SeaGen), Reveal Genomics, Sanofi, Systimmune, Sumitovant Biopharma, Tango Therapeutics, Umoja Biopharma, Zentalis and Zymeworks; has received institutional research funding from AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Gilead, Jazz Pharmaceuticals, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer and Seattle Genetics; and travel support from Eli Lilly, Gilead, Jazz Pharmaceuticals, Pfizer and Sanofi. A.P. has acted as an adviser and/or consultant to Amgen, Bristol Myers Squibb, Guardant Health, Lilly, MSD, Novartis, Oncolytics Biotech, Peptomyc, Pfizer, Puma, Reveal Genomics, Roche and SL; has acted as a speaker for Amgen, Bristol Myers Squibb, Daiichi Sankyo, Nanostring Technologies, Novartis, Pfizer and Roche; has received institutional research funding from Astellas, Celgene, Boehringer, Medica Scientia Innovation Research, Nanostring, Novartis, Pfizer, Roche, SL and Sysmex Europa GmbH; holds stocks in Reveal Genomics and SL; and is listed as a co-inventor on patent applications (CT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369). The other authors declare no competing interests.